中国肺癌杂志
中國肺癌雜誌
중국폐암잡지
CHINESE JOURNAL OF LUNG CANCER
2013年
10期
524-528
,共5页
林琳%王彬%郝学志%邢镨元%李峻岭%张湘茹%石远凯
林琳%王彬%郝學誌%邢鐠元%李峻嶺%張湘茹%石遠凱
림림%왕빈%학학지%형보원%리준령%장상여%석원개
肺肿瘤%EGFR-TKIs%缓慢进展%生存期
肺腫瘤%EGFR-TKIs%緩慢進展%生存期
폐종류%EGFR-TKIs%완만진전%생존기
Lung neoplasms%EGFR-TKIs%Gradual progression%Overall survival
背景与目的表皮生长因子受体酪氨酸激酶抑制剂(epidermal growth factor receptor tyrosine kinase inhibi-tors, EGFR-TKIs)目前广泛应用于晚期非小细胞肺癌(non-small cell lung cancer, NSCLC),特别是存在表皮生长因子受体EGFR基因突变的肺腺癌患者。对于治疗后进展的患者,后续治疗未取得共识。本文总结EGFR-TKIs治疗后缓慢进展的晚期NSCLC患者接受不同后续治疗方法的近期疗效、毒性反应和总生存期,评价不同治疗方法的意义。方法回顾性分析我院2003年9月-2011年12月期间32例接受EGFR-TKIs治疗后缓慢进展的晚期NSCLC患者,分别继续接受EGFR-TKIs治疗或化疗。结果 EGFR-TKIs维持治疗组患者的中位生存时间为36.0个月,在改行化疗的患者中,化疗有效率为43.75%,总的临床获益率(完全缓解+部分缓解+稳定)为87.5%。中位生存时间为15.5个月。主要的毒性反应为恶心呕吐等消化道反应和血液学毒性。结论在EGFR-TKIs治疗后出现肿瘤缓慢进展的患者中,维持原EGFR-TKIs治疗是可行的选择。
揹景與目的錶皮生長因子受體酪氨痠激酶抑製劑(epidermal growth factor receptor tyrosine kinase inhibi-tors, EGFR-TKIs)目前廣汎應用于晚期非小細胞肺癌(non-small cell lung cancer, NSCLC),特彆是存在錶皮生長因子受體EGFR基因突變的肺腺癌患者。對于治療後進展的患者,後續治療未取得共識。本文總結EGFR-TKIs治療後緩慢進展的晚期NSCLC患者接受不同後續治療方法的近期療效、毒性反應和總生存期,評價不同治療方法的意義。方法迴顧性分析我院2003年9月-2011年12月期間32例接受EGFR-TKIs治療後緩慢進展的晚期NSCLC患者,分彆繼續接受EGFR-TKIs治療或化療。結果 EGFR-TKIs維持治療組患者的中位生存時間為36.0箇月,在改行化療的患者中,化療有效率為43.75%,總的臨床穫益率(完全緩解+部分緩解+穩定)為87.5%。中位生存時間為15.5箇月。主要的毒性反應為噁心嘔吐等消化道反應和血液學毒性。結論在EGFR-TKIs治療後齣現腫瘤緩慢進展的患者中,維持原EGFR-TKIs治療是可行的選擇。
배경여목적표피생장인자수체락안산격매억제제(epidermal growth factor receptor tyrosine kinase inhibi-tors, EGFR-TKIs)목전엄범응용우만기비소세포폐암(non-small cell lung cancer, NSCLC),특별시존재표피생장인자수체EGFR기인돌변적폐선암환자。대우치료후진전적환자,후속치료미취득공식。본문총결EGFR-TKIs치료후완만진전적만기NSCLC환자접수불동후속치료방법적근기료효、독성반응화총생존기,평개불동치료방법적의의。방법회고성분석아원2003년9월-2011년12월기간32례접수EGFR-TKIs치료후완만진전적만기NSCLC환자,분별계속접수EGFR-TKIs치료혹화료。결과 EGFR-TKIs유지치료조환자적중위생존시간위36.0개월,재개행화료적환자중,화료유효솔위43.75%,총적림상획익솔(완전완해+부분완해+은정)위87.5%。중위생존시간위15.5개월。주요적독성반응위악심구토등소화도반응화혈액학독성。결론재EGFR-TKIs치료후출현종류완만진전적환자중,유지원EGFR-TKIs치료시가행적선택。
Background and objective hTe epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have been widely used in the treatment of the advanced non-small cell lung cancer (NSCLC), especially in the adeno-carcinoma patients with activating EGFR mutations. But there is no published overview of the following treatment. hTis report through observing the efficacy, toxicity and overall survival of different treatments to the advanced NSCLC patients who had gradual progression atfer EGFR-TKIs, evaluates the inlfuence of the continued treatment and switching chemotherapy. Methods Retrospective review is conducted on 32 cases of advanced NSCLC patients who experienced treatment failure of EGFR-TKIs. One group accepted the continued treatment and the other group accepted the switching chemotherapy. Results hTe median overall survival of the continued treatment group is 36.0 months. hTe respose rate of the switching chemotherapy group is 43.75%, and clinical benefit rate (complete and partial response and stable disease) is 87.5%. The median overall survival is 15.5 months. hTe main toxicities are nausea, vomiting and hematological toxicities. Conclusion For the advanced NSCLC patients who had gradual progression atfer EGFR-TKIs, the continued treatment is one of the acceptable choices.